Elsevier

Cancer Epidemiology

Volume 58, February 2019, Pages 137-145
Cancer Epidemiology

Liquid biopsy: miRNA as a potential biomarker in oral cancer

https://doi.org/10.1016/j.canep.2018.12.008Get rights and content

Highlights

  • Circulating miRNAs are extremely stable in high pH, temperatures and RNase treatment.

  • Circulating miRNAs in serum, plasma and saliva of oral cancer patient can be used as biomarkers.

  • Population and stage of cancer specific miRNAs need to be identified as biomarkers.

  • Knowledge of prognostic and therapeutic potential of these miRNAs can be used in treatment.

  • Uniformly deregulated circulating miRNAs need to be tested among different populations.

Abstract

Oral cancer is one of the leading cancers in South-Asian countries. Despite the easy access of the oral cavity, the detection and five year survival rates of OSCC patients are dismal. Identification of non-invasive biomarkers to determine the progression and recurrence of OSCC could be of immense help to patients. Recent studies on oral cancer suggest the importance of non-invasive biomarker development. Micro-RNAs (miRNAs) are one of the important components of the cell-free nucleic acids available in different body fluids. Here, we have reviewed the current understanding of circulating miRNAs as non-invasive biomarkers in different body fluids of oral cancer patients. A number of circulating miRNAs are found to be common in the body fluids of OSCC patients, while many of these are study specific, the possible sources of this variability could be due to differences in sample processing, assay procedure, clinical stage of the disease, oral habit and environmental factors. The prognostic and therapeutic significance of these circulating miRNAs are suggested by several studies. Mir-371, mir-150, mir-21 and mir-7d were found to be potential prognostic markers, while mir-134, mir-146a, mir-338 and mir-371 were associated with metastases. The prognostic markers, mir-21 and mir-7d were also found to be significantly correlated with resistance to chemotherapy, while mir-375, mir-196 and mir-125b were significantly correlated with sensitivity to radiotherapy. Despite the promising roles of circulating miRNAs, challenges still remain in unravelling the exact regulation of these miRNAs before using them for targeted therapy.

Introduction

Head and neck squamous cell carcinoma (HNSCC), the ninth most common neoplasm across the globe, is a significant cause of cancer morbidity and mortality [1]. HNSCC mainly comprises neoplasms of the oral cavity, pharynx, larynx, paranasal synapses, nasal cavity and salivary glands. According to the recent GLOBOCAN 2018 report, cancers of the lip and oral cavity are the most frequent cancer in Melanesia and South Central Asia [2]. It is the leading cause of cancer death among men in India and Sri Lanka [2]. Oral squamous cell carcinoma (OSCC) is the major component of HNSCC, accounting for about 90% of all oral malignancies representing a major global burden with an estimated 300,373 cases per annum [1]. The recent GLOBOCAN 2018 report estimated 354,864 new cases of lip and oral cavity cancer per annum with around 1.8 million deaths predicted in 2018 [2]. Oral cancer consists of malignant neoplasms arising in the lips, hard palate, upper and lower alveolar ridges, sublingual region, buccal mucosa, anterior two-thirds of the tongue, retromolar trigone and floor of the mouth [3,4]. Variations in the incidence of oral cancer across the globe are generally attributed to differences in habits practised by different populations [1]. The habits of smoking, chewing tobacco, areca nut, betel quid, alcohol consumption, poor oral hygiene, chronic mechanical trauma and Human Papillomavirus (HPV) infections are considered to be the major factors for the higher incidence of OSCC in India [3,5]. Oral potentially malignant disorders (OPMD) are also reported to advance to malignancies, if left untreated [5].

One of the main reason for poor survival of oral cancer patients is late detection. Clinical examination of the oral cavity and biopsy of the suspected lesion followed by histological analysis are generally used for diagnosis. Biopsy is an invasive procedure in which a portion of the suspected malignant tissue is obtained and further subjected to specialized and sophisticated histopathology or cytology procedures. Biopsy is gold standard till date in detecting the histopathological type of a neoplasms and its degree of differentiation, and has been in practice since the 11th century [6,7]. Sometimes it becomes difficult to procure biopsy material due to inaccessibility of certain tumors, physical pain involved after the procedure, surgical complications, financial burden and lack of trained clinicians. Cell free nucleic acids (cfNAs), such as cell free DNA and RNA are present in body fluids of all individuals [8,9]. The expression profile of cfNAs varies between different disease states, so liquid biopsy has potential as a minimally invasive method for detection of disease, including malignant neoplasms [10,11].

Liquid biopsy first came on the scene in 1984 when Mandel and Metais referred to cfNAs as free floating nucleic acids in blood [8,9]. The source of cfNA in body fluids of cancer patients is considered to be apoptotic and necrotic cells of the neoplasm itself, and of other cells in the tumour microenvironment. Secretion has also been suggested as a potential source of cfNA [8]. Circulating tumor cells were first observed in the blood of a cancer patient in 1869, but it took more than a century before their entry into commerce. The clinical utility of liquid biopsy was first realized in 1994 when point mutations of a gene were successfully detected from the cfDNA derived from the plasma of acute myelogenous leukemia patients, whereas the DNA derived from the cellular component of blood did not show any mutations [12].

MiRNAs are usually secreted into the body fluids in membrane bound vesicles known as exosomes. Exosomes are 50–100 nm-sized membrane bound molecular carriers that play important roles in cell-cell interaction [13]. Release of miRNAs from exosomes is a significant mechanism of genetic exchange between cells [14]. Circulating miRNAs are extremely stable and can be conveniently used as informative biomarkers for complex diseases such as cancers [15]. Recent studies of circulating miRNAs in plasma, serum, and other body fluids show that miRNAs secreted from a particular cell type not only has a local action, but may also act at distant sites [16,17].

Section snippets

Serum/plasma miRNA as a biomarker in oral cancer

Circulating miRNAs have been demonstrated to show different levels in the body fluids of OSCC patients compared to healthy individuals [18,19]. MiRNAs are highly stable in the serum or plasma leading to rising hopes for their future use as cancer biomarkers [20]. Circulating miRNAs are not digested by RNase and are stable at high pH, after boiling and after multiple freeze-thaw cycles [21,22]. While bound to the argonaute protein, miRNAs are stable in the extracellular environment whether

Salivary miRNA as a biomarker in oral cancer

“Whole mouth fluid”(WMF) is a complex biological fluid containing saliva secreted by three paired major salivary glands, namely parotid, submandibular and sublingual, plus a large number of widely distributed minor salivary glands. There is a significant contribution from gingival crevicular fluid, an inflammatory serum and cellular exudates [35]. Moreover, WMF contains serum and desquamated epithelial cells from the oral mucosa, including some leucocytes, especially if there is ulceration or

Similar and dissimilar expression profiles of miRNAs in the saliva/WMF and serum/plasma of OSCC patients

Several miRNAs are reported to show similar concentrations in different body fluids of OSCC patients. For example, miR-24, miR-146a, miR-184, miR-31, miR-451 and miR-26a have been reported to be mostly uniformly expressed both in the saliva/WMF and serum or plasma of OSCC patients compared to healthy controls (Table 3). The presence of these miRNAs in different body fluids as well as among different populations suggests that they can be used as biomarkers for oral cancer detection irrespective

MiRNAs as prognostic biomarkers in oral cancer

The expression patterns of certain miRNAs have shown positive correlation with clinical stage, lymph node metastasis and patient survival, indicating that these miRNAs can act as prognostic predictors in OSCC. Higher expression levels of miR-372 is shown to induce nodal metastasis and poor prognosis of oral carcinoma [53], while miR-134 showed association with number of metastases in HNSCC [54]. MiR-146a is reported to show increased metastasis by down-regulating the expression of IRAK1, TRAF6

Therapeutic role of circulating miRNAs in oral cancer

The ability to manipulate miRNA expression and function by local and systemic delivery of miRNA inhibitors or miRNA mimics has recently gained immense interest as a novel therapeutic approach [68,69]. The advantage of miRNA based cancer therapy lies in the ability of miRNAs to concurrently target multiple effectors of pathways involved in cell proliferation, differentiation, and survival. However, the major challenges are in vivo delivery of these polyanionic oligonucleotides. Naked miRNAs

Conclusion

In oral cancer, the lesion is usually visible and easily accessible for procuring biopsy, therefore, liquid biopsy may sound redundant in oral cancer diagnostics. But, biopsy is an invasive procedure and involves physical pain to the patients. Hence, liquid biopsy plays a pivotal role in non-invasive detection of cancer at early stages of the disease.

Several miRNAs have been reported to be deregulated in the body fluids of OSCC patients compared to healthy controls suggesting that these miRNAs

Funding

This work was supported by the CSIR extramural (Grant no 27(0306)/14//EMR-II) to RC, JR and KC and ISI intramural funding to RC.

Conflict of interest

The authors declare no relevant conflicts of interest.

Acknowledgments

SM is thankful to CSIR for providing the CSIR-NET fellowship.

References (118)

  • G. Childs

    Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma

    Am. J. Pathol.

    (2009)
  • M.H. Shaikh

    Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers

    Oral Oncol.

    (2018)
  • M.H. Shaikh

    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?

    Oral Oncol.

    (2017)
  • L. Lu

    MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis

    Biomed. Pharmacother.

    (2014)
  • H.M. Jung

    Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer

    J. Biol. Chem.

    (2012)
  • J.Y. Xu

    MiR-25-3p attenuates the proliferation of tongue squamous cell carcinoma cell line Tca8113

    Asian Pac. J. Trop. Med.

    (2013)
  • Y.C. Lu

    Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer

    Clin. Biochem.

    (2015)
  • P. Li

    MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1

    J. Hematol. Oncol.

    (2017)
  • H. Chi

    miR-194 regulated AGK and inhibited cell proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signaling

    Biomed. Pharmacother.

    (2015)
  • A.F. Christopher et al.

    Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma

    Gene

    (2016)
  • B. Gupta et al.

    Global epidemiology of head and neck cancers: a continuing challenge

    Oncology

    (2016)
  • F. Bray

    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

    CA Cancer J. Clin.

    (2018)
  • L.A. Torre

    Global cancer statistics, 2012

    CA Cancer J. Clin.

    (2015)
  • B. Basu

    Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India

    Clin. Epigenet.

    (2017)
  • J.P. Shah et al.
  • E. Crowley

    Liquid biopsy: monitoring cancer-genetics in the blood

    Nat. Rev. Clin. Oncol.

    (2013)
  • A. Diamantis et al.

    Fine-needle aspiration (FNA) biopsy: historical aspects

    Folia Histochem. Cytobiol.

    (2009)
  • H. Schwarzenbach et al.

    Cell-free nucleic acids as biomarkers in cancer patients

    Nat. Rev. Cancer

    (2011)
  • Ginkel

    Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: a systematic review of the literature

    Oral Oncol.

    (2017)
  • H. Mansour

    Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection

    Front. Genet.

    (2014)
  • V. Vasioukhin

    Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia

    Br. J. Haematol.

    (1994)
  • C. Thery et al.

    Membrane vesicles as conveyors of immune responses

    Nat. Rev. Immunol.

    (2009)
  • N. Kosaka et al.

    Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis

    Cancer Sci.

    (2010)
  • J.A. Weber

    The microRNA spectrum in 12 body fluids

    Clin. Chem.

    (2010)
  • M.A. Cortez

    MicroRNAs in body fluids—the mix of hormones and biomarkers

    Nat. Rev. Clin. Oncol.

    (2011)
  • S.A. Maclellan

    Differential expression of miRNAs in the serum of patients with high-risk oral lesions

    Cancer Med.

    (2012)
  • L. Ayaz

    Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma

    J. Cancer Res. Clin. Oncol.

    (2013)
  • K. Wang

    Export of microRNAs and microRNA-protective protein by mammalian cells

    Nucleic Acids Res.

    (2010)
  • C. Chakraborty et al.

    Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers

    Tumour Biol.

    (2016)
  • J.D. Arroyo

    Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma

    Proc. Natl. Acad. Sci. U. S. A.

    (2011)
  • A. Turchinovich

    Characterization of extracellular circulating microRNA

    Nucleic Acids Res.

    (2011)
  • Y. Yan

    Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients

    Oncotarget

    (2017)
  • R. Shah

    Discordant expression of circulating microRNA from cellular and extracellular sources

    PLoS One

    (2016)
  • K. Wang

    Comparing the microRNA spectrum between serum and plasma

    PLoS One

    (2012)
  • H. Ple

    The repertoire and features of human platelet microRNAs

    PLoS One

    (2012)
  • H.H. Cheng

    Plasma processing conditions substantially influence circulating microRNA biomarker levels

    PLoS One

    (2013)
  • M.B. Kirschner

    The impact of hemolysis on cell-free microRNA biomarkers

    Front. Genet.

    (2013)
  • V. Koberle

    Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers

    PLoS One

    (2013)
  • J.A. Makarova

    Circulating microRNAs

    Biochemistry (Mosc.)

    (2015)
  • K.E.A. Max

    Human plasma and serum extracellular small RNA reference profiles and their clinical utility

    Proc. Natl. Acad. Sci. U. S. A.

    (2018)
  • Cited by (93)

    View all citing articles on Scopus
    1

    Present address: Burdwan Dental College and Hospital, Power House Road, Shyamlal Colony, Khosbagan, Bardhaman, West Bengal, 713101, India.

    View full text